CYP450 2D6 Genotype and Flecainide Efficacy in the Treatment of Patients with Lone Atrial Fibrillation

Authors

  • Therese Fuchs Assaf Harofeh Medical Center
  • Elvera L. Baron
  • Adina Bar-Haim
  • Patricia Benveniste-Levkovitz
  • Amram Torjman
  • Moshe Sharist
  • Marina Leitman
  • Shmuel Bar-Haim

DOI:

https://doi.org/10.2015/hc.v7i4.521

Keywords:

CYP450 2D6 Genotype, Flecainide, Atrial Fibrillation

Abstract

Background: CYP2D6 has been linked to one of four phenotypes: a) ultra-rapid metabolizers (UM), with multiple gene copies; b) extensive metabolizers (EM), with a single wild type gene copy, considered normal; c) intermediate (IM) metabolizer, with decreased enzymatic activity; and d) poor metabolizers (PM) with no detectable enzymatic activity.  By altering the drug dose-plasma concentration relationship, these differences may lead to severe toxicity and or therapeutic failure.

Objectives: The aim of this study was to determine the correlation between CYP2D6 polymorphisms and both efficacy and magnitude of adverse reactions of flecainide, a class IC antiarrhythmic agent.

Methods: Patients with Lone Atrial fibrillation (AF) were enrolled in a 2-arm prospective study: patients started on flecainide at the initial visit, then were followed up at 3 and 6 months intervals (arm 1) or exhibited AF recurrences on flecainide, defined as treatment failure (arm 2).  Data about recurrence of AF, side effects, and demographics were collected. Genotyping was performed using AmpliChipTM CYP450.

Results: A total of 26 lone AF patients were enrolled (12 in arm 1, and 14 in arm 2).  The mean age was 47± 10.8 years and 56.2 ± 10.8 years respectively.  Among the analyzed phenotypes the following distribution was found: 1/26 (3.8%) UM, 19/26 (73%) EM, 5/26 (19%) IM, 1/26 (3.8%) PM.

Conclusions: In this small series of patients with lone atrial fibrillation, most patients were found to be extensive metabolizers of flecainide.  There was no statistically significant correlation between the patients' genotype, and flecainide efficacy / side effects.

Author Biography

Therese Fuchs, Assaf Harofeh Medical Center

Cardiology department

Director of EP

Downloads

Published

2012-08-19

Issue

Vol. 7 No. 4 (2012)

Section

ORIGINAL ARTICLES

License

Authors who publish with this journal agree to the following terms:

a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).